chufangao/CTO huggingface dataset:
Clinical trial NCT03029143: Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Official title: A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
Acronym: ENTERPRET
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 278.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-29
Primary completion date: 2020-10-16
Completion date: 2020-10-16
Baseline population: Safety analysis set Included all participants who were enrolled and received at least one dose of study medication.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04682639: A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis
Acronym: VOYAGE
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 108.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-12-15
Primary completion date: 2022-09-30
Completion date: 2023-06-30
Baseline population: All participants who were randomized to study treatment.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02530437: Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
Official title: A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was available. The sponsor made a decision to stop development of this drug Taladegib.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-07
Primary completion date: 2022-01-07
Completion date: 2022-01-07
Clinical trial NCT03186417: Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Official title: Cell-Based Therapy in Rheumatoid Arthritis: Proof of Concept Phase 1 Trial
Sponsor: MetroHealth Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: slow enrollment during covid and lack of funds to continue
Enrollment: 10.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-12-15
Primary completion date: 2023-04-30
Completion date: 2023-05-31
Plan to share individual participant data: NO
Clinical trial NCT03697720: Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain
Official title: Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain
Sponsor: NorthShore University HealthSystem (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 26.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-09
Primary completion date: 2020-11-23
Completion date: 2023-09-27
Limitations and caveats: There was some loss to follow-up. We did not systematically query for adverse events.
Plan to share individual participant data: NO
Clinical trial NCT03703102: Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (AD)
Sponsor: Kyowa Kirin Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 274.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-10-22
Primary completion date: 2020-02-06
Completion date: 2020-11-12
Baseline population: One subject who was randomized to the 600 mg Q4W group did not receive any study treatment due to consent withdrawal before the start of the treatment. They are not included in baseline or any of the analysis sets.
Plan to share individual participant data: NO
Clinical trial NCT04044742: A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee
Official title: A Phase 3 Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Administration of Resiniferatoxin Versus Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee
Sponsor: Sorrento Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: To be replaced by a different protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-31
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT04223843: A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
Official title: A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study to Compare the Efficacy of Inhaled Tiotropium + Olodaterol, Fixed Dose Combination (5 mcg/5mcg) vs. Placebo Delivered by Respimat Inhaler in Patients With Moderate to Severe COPD, Stratified by Peak Inspiratory Flow Rate [TRONARTO].
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 213.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-08
Primary completion date: 2020-09-07
Completion date: 2020-09-29
Baseline population: Treated Set (TS): This patient set included all randomised patients who were dispensed trial medication and were documented to have taken any dose of trial medication. The TS was used for demographics and baseline disease characteristics, concomitant therapies, treatment exposure, and safety analysis.
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement. Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT04003623: Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Official title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was closed due to lack of enrollment.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-31
Primary completion date: 2020-06-12
Completion date: 2020-06-12
Baseline population: No participants were enrolled in Cohort B.
Limitations and caveats: The Sponsor made a decision unrelated to safety to halt study enrollment. Due to early termination of the study with only1 participant, no analysis of efficacy endpoints was done.
Plan to share individual participant data: YES
IPD sharing description: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Clinical trial NCT05492695: Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study
Official title: TOGETHER STUDY: Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study
Acronym: TOGETHER
Sponsor: Diamond Headache Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Stopped from financial sponsor due to inability to enroll participants.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-01
Primary completion date: 2023-09-28
Completion date: 2023-09-28
Plan to share individual participant data: NO
Clinical trial NCT03613792: Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy
Official title: Remifentanil Plus Ketamine Versus Midazolam Plus Fentanyl for Dynamic Flexible Bronchoscopy: Randomized Double-blind Clinical Trial
Sponsor: Beth Israel Deaconess Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Change in procedure means limited value for study question
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-09-30
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT03184571: Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
Official title: A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung
Sponsor: BerGenBio ASA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 106.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-17
Primary completion date: 2022-10-27
Completion date: 2022-10-27
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in the article, after deidentification \[text, tables, figures and appendices\].
IPD time frame: Beginning 3 months and ending 5 years following article publication
IPD access criteria: Proposal should be directed to HYPERLINK mailto:clinical@bergenbio.com clinical@bergenbio.com. To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT04825860: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
Official title: A Randomized, Double-blind, Parallel-group, Placebo Controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in Acutely Psychotic Patients With Schizophrenia, Followed by an Open-label Extension Phase
Sponsor: Sumitomo Pharma Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Due to company business strategy
Enrollment: 83.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-29
Primary completion date: 2023-10-12
Completion date: 2023-10-19
Plan to share individual participant data: NO
Clinical trial NCT02663271: TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Official title: A Phase 2, Multi-center, Single Arm, Histologically Controlled Study Testing the Combination of TTFields and Pulsed Bevacizumab Treatment in Patients With Bevacizumab-refractory Recurrent Glioblastoma
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: stagnant enrollment
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-12-19
Primary completion date: 2021-06-11
Completion date: 2021-06-11
Plan to share individual participant data: NO
Clinical trial NCT03292731: Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth
Official title: Relationship Between Plasma Concentration of (Hydroxyprogesterone Caproate) 17-OHPC and Preterm Birth
Acronym: PRO
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: grant funding cycle ended
Enrollment: 159.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-02-12
Primary completion date: 2021-09-02
Completion date: 2021-09-02
Baseline population: Includes those who were compliant with study procedures and continued treatment
Limitations and caveats: Statistical analysis limited due to inadequate enrollment and subsequent small sample size and few cases of sPTB.
Plan to share individual participant data: YES
IPD sharing description: Deidentified data to be shared include plasma 17-OHPC concentrations , rates of sPTB, and data on maternal adverse effects and neonatal outcomes
IPD time frame: These data will be eligible to the recruiting centers after the main data are published. they will have 18 months to request secondary analyses . other researchers will have access to the data after that period.
IPD access criteria: To be determined by the OPRC steering committee.
Clinical trial NCT04293172: Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
Official title: A Randomised, Double Blind, Parallel Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Number of Vaso-Occlusive Crises in Paediatric Patients Aged 6 Months to <18 Years With Sickle Cell Disease (HESTIA5)
Acronym: HESTIA5
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Study halted prematurely, prior to enrolment of first patient.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-30
Primary completion date: 2022-10-10
Completion date: 2022-10-10
Clinical trial NCT03743025: Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
Official title: Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was terminated following the Data and Safety Monitoring Board (DSMB) review due to concerns with perioperative use of the study drug.
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-08
Primary completion date: 2023-05-02
Completion date: 2023-05-02
Plan to share individual participant data: NO
Clinical trial NCT02401035: PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects
Official title: AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS OF SINGLE AND MULTIPLE INTRAVENOUS DOSES OF PANTOPRAZOLE IN TWO AGE COHORTS OF HOSPITALIZED PEDIATRIC SUBJECTS 1 TO 16 YEARS OF AGE WHO ARE CANDIDATES FOR ACID SUPPRESSION THERAPY
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study was terminated early due to the infeasibility of enrolling the required number of participants per protocol in the 1 \<2 years of age cohort.
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-09
Primary completion date: 2021-06-18
Completion date: 2021-06-18
Baseline population: All enrolled participants were included in analysis.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03654976: Mite Asthma Pediatric Immunotherapy Trial
Official title: A Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) Sublingual Immunotherapy (SLIT)-Tablet in Children and Adolescents (5-17 Years) With HDM Allergic Asthma
Acronym: MAPIT
Sponsor: ALK-Abelló A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 533.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-22
Primary completion date: 2022-05-18
Completion date: 2022-05-31
Baseline population: All randomized participants
Limitations and caveats: Enrollment was paused at the outbreak of the COVID-19 pandemic. During the COVID-19 pandemic the asthma exacerbation rate decreased both in the trial population (blinded data) and in the general asthma population. It was therefore deemed difficult to recruit participants based on a history of recent asthma exacerbations. The sponsor decided to end the trial with the completed participants on 10-Aug-2022 due to the severe impact of COVID-19.
Plan to share individual participant data: NO
Clinical trial NCT03158610: Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer
Official title: Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer
Sponsor: Ruijin Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Difficult to enrollment patient
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-29
Primary completion date: 2021-04-28
Completion date: 2021-04-28
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02293837: Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Official title: Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)
Acronym: EXTEND
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 136.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-03-12
Primary completion date: 2019-07-10
Completion date: 2020-08-31
Baseline population: Randomized participants in each cohort were randomized 2:1 to tocilizumab or placebo, respectively.
Plan to share individual participant data: YES
IPD sharing description: The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD time frame: On average, within 24 months after database lock for the trial.
IPD access criteria: Open access.
Clinical trial NCT05149807: Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
Official title: A Randomized, Double-Blind, Multi-Center Phase II/III Clinical Study of PD-L1 Antibody/TGF-βRII (SHR-1701) Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin Versus Placebo Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin as Perioperative Treatment in Subjects With Resectable Gastric Cancer or Gastroesophageal Junction Cancer
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: R\&d strategy adjustment
Enrollment: 81.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-26
Primary completion date: 2024-04-03
Completion date: 2024-04-03
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05137002: A Study of CIN-107 in Patients With Uncontrolled Hypertension
Official title: A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 8 Weeks of Treatment in Patients With Uncontrolled Hypertension
Acronym: HALO
Sponsor: CinCor Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 249.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-12-07
Primary completion date: 2022-09-13
Completion date: 2022-10-10
Plan to share individual participant data: NO
Clinical trial NCT04836559: A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects With Focal Onset Seizures With Suboptimal Response to Levetiracetam or Brivaracetam
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 110.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-18
Primary completion date: 2024-02-08
Completion date: 2024-02-08
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinicaltrials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04930770: Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination
Official title: Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination
Acronym: VAX-TRES
Sponsor: Fundacion Clinic per a la Recerca Biomédica (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No candidates for the trial (all patients have received the third dose of the vaccine)
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-01
Primary completion date: 2021-12-01
Completion date: 2022-03-01